Regulatory News

August 2010

• Antibody Licence Agreement with Cancer Research Technology

July 2010

• Withdrawal from PLUS and Admission to AIM
• Grant of Options - Grant of Options
• Final Results for the year ended 30 April 2010

June 2010

• Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
• SCIB1 Phase I Trial Commences - First Patient Treated
• Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
• ICHOR Medical Systems, Inc Quantification of Share Options under License and Supply Agreement

May 2010

• National Institutes of Health Licensing Agreement
• Clinical Trial Approval for SCIB1 melanoma vaccine study
• Placing

April 2010

• Placing of New Ordinary Shares

March 2010

• Result of Open Offer
• Director’s Dealings
• Open Offer

February 2010

• Clinical Trial Application for SCIB1 melanoma vaccine

January 2010

• Interim Results for the six month period to 31 October 2009

November 2009

• Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
• Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
• Result of AGM

September 2009

• Preliminary Results for the Year Ended 30 April 2009

August 2009

• Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery

July 2009

• Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
• Scancell licenses key ImmunoBody® patents from Merck Serono
• Change of Advisor

January 2009

• Scancell Receives GBP250,000 emda Grant
• GMP Manufacture Deal With Cobra

• Interim Results for the six month period to 31 October 2008

December 2008

• Issue of Equity

November 2008

• Notice of Results

September 2008

• Admission to PLUS and Start of Trading
• Audited Final Results for the Year Ended